Bio Syntech Inc. Signs a Retainer Agreement With Cleary & Oxford Associates.Business Editors QUEBEC--(BUSINESS WIRE) Bio Syntech Inc (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BSYI) Bio Syntech Inc. (OTCBB:BSYI) today announced the signing of a retainer agreement A retainer agreement is work for hire contract intermediate between simple contracting and direct employment but essentially still contracting. One element that distinguishes it from any other service contract is that a primary consideration which the buyer purchases is an option with Cleary & Oxford Associates. Under this agreement, Bio Syntech Inc. will use Cleary & Oxford Associates' expertise to structure licensing agreements with its current and potential partners. Cleary & Oxford Associates provides strategic advisory services advisory services advisory services provided to the public, in their capacity as owners and managers of animals, are an important part of veterinary science. They may be provided by government bureaux, by commercial companies who deal in pharmaceuticals or animals or animal to medical device companies, primarily arranging mergers, acquisitions, divestitures, licensing arrangements and management buyouts. Founded in 1978, the firm has consummated transactions with over 100 companies, including most of the major medical product corporations in the United States, as well as healthcare companies in Europe, Asia and Australia. "We are very pleased with the working relationship we are establishing with Cleary & Oxford Associates. We firmly believe that this experienced and highly capable firm, very well-known for providing valuable contributions through advisory services within the healthcare world, will give Bio Syntech the opportunity to meet its goals. Bio Syntech is committed, more than ever, to creating strong partnerships with biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. and pharmaceutical companies, and is successfully progressing towards meeting its current objectives," said Dr. Amine amine (əmēn`, ăm`ēn): see under amino group. amine Any of a class of nitrogen-containing organic compounds derived, either in principle or in practice, from ammonia (NH3). Selmani, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bio Syntech Inc. Bio Syntech Inc. is an advanced biomaterials company specializing in tissue repair and in the delivery of biotherapeutic products. This press release contains certain "forward-looking" statements, as defined in the United States Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in the company's filings with the regulatory authorities having jurisdiction. No regulatory authority has approved or disapproved the content of this release. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion